Category: Biolase Technology Inc.
Biolase wins a nod from the FDA to expand its soft-tissue laser to 19 different markets.
Biolase (NSDQ:BIOL) won FDA approval for the use of its 940nm Diolase 10 laser in a range of different markets. The federal watchdog agency also cleared 80 new procedures for the device.
The Irvine, Ca-based dental laser company said it can now sell into more than 20 new markets, including ear, nose and throat, arthroscopy, dermatology, plastic surgery and ophthalmology.
Dental devices maker Biolase gets some Wall Street love on positive cash flow expectations for Q4 2012.
Dental laser maker Biolase (NSDQ:BIOL) released a preliminary earnings report, expecting to positive cash flow for Q4 and the full year of 2012.
The optimistic outlook sent BIOL shares up 2.2% on the day to close at $2.77 from an open of $2.70 this morning.
Biolase Inc. lands 510(k) clearance for its EPIC 10 diode soft tissue laser to improve patient comfort.
California-based dental laser company Biolase (NSDQ:BIOL) touted FDA clearance and CE Mark approval for its EPIC 10 diode soft tissue laser to help dentists control the laser energy level and improve patient comfort.
Revenues for aesthetic medical device companies largely rise during the 2nd quarter, as purchasing and volume growth trend up, according to a MassDevice.com analysis.
The market for aesthetic medical devices gained some ground during the 2nd quarter, a MassDevice.com analysis shows, although healthy sales growth didn't necessarily translate into healthy bottom lines for all comers.
Stryker's plans to cut more than 100 jobs by closing 2 New York manufacturing facilities will begin in September and continue on a rolling basis until the end of the year, just ahead of implementation of the 2.3% medical device tax.
Stryker (NYSE:SYK) is making good on plans to cut more than 100 positions by closing 2 New York manufacturing plants, moves that the company previously attributed to attempts to cut costs ahead of the coming 2.3% medical device tax.
Thoratec and HeartWare will duke it out with "basically equivalent" heart pump technologies; also, venture capitalists look for devices that replace drugs; Biolase boasts a new Nasdaq ticker; plus, a Funding Roundup and analysts' ups and downs.